Line Systems ApS Due Diligence

Run due diligence on Line Systems ApS: check compliance and get alerts when suppliers or ownership change.

Denmark · owned by Lighthaus Copenhagen ApS (Denmark) · linesystems.io · 19 vendors

Line Systems ApS develops digital diabetes care solutions, specifically the Line Portal platform for aggregation and visualization of diabetes-related data. The company provides healthcare providers with comprehensive patient data management tools and secure, compliant platforms for diabetes care.

Resilience scores

Technology vendors

Services catalogue

22 services in catalogue across 6 categories; runs on 19 sub-vendors.

Insights

Last updated 2026-09-13 · revision 21

19 direct vendors, 221 subvendors

Direct vendors by controlling owner country (sample)

Subvendors by controlling owner country (sample)

Compliance

5 in-scope frameworks identified; showing 3.

SOC 2 (source) — No public evidence

GDPR (source) — No public evidence

Evidence: https://linesystems.io

EU MDR 2017 — Evidence found

Evidence: https://linesystems.io

Financials

Three-year financials

Financial Resilience Score: 4/10

Line Systems ApS has achieved a meaningful regulatory milestone in obtaining CE marking under EU MDR 2017/745, which represents a significant barrier to entry and provides a degree of competitive protection. The company is embedded in reputable European health-tech ecosystems (Copenhagen Health Tech Hub, Barcelona Health Hub) and participates in the ADAPT-T2D Consortium, suggesting access to non-dilutive grant funding channels and clinical validation partnerships. Its GDPR-compliant on-premise architecture is well-suited to the data sovereignty requirements of European public health systems, providing a structural selling advantage over US-hosted cloud competitors. However, the overall financial resilience is assessed as low-to-moderate due to the company's apparent early-stage status. No revenue, EBIT, or equity figures are publicly available, and the company likely files abbreviated accounts that do not disclose revenue. This opacity makes it impossible to confirm operational sustainability or funding runway. The business is almost certainly dependent on equity investment and/or public grants rather than self-sustaining commercial revenue. The competitive landscape is challenging, with well-funded global players such as Dexcom Clarity, Medtronic CareLink, Glooko, and Tidepool already operating in the diabetes data management space. Long hospital procurement cycles (12–36 months) create significant cash flow pressure for a small team, and the single-product, single-disease-area focus creates material concentration risk. Ongoing MDR compliance obligations (post-market surveillance, vigilance reporting) impose a continuous cost burden disproportionate to the likely team size. Without verified financial statements, confirmed funding rounds, or disclosed revenue, the resilience score is constrained. The regulatory achievement and ecosystem positioning are genuine strengths, but the absence of any confirmable financial foundation limits confidence in near-term sustainability.

Key strengths: CE mark under EU MDR 2017/745 — significant regulatory barrier to entry, GDPR-compliant on-premise architecture suited to European public health procurement, Membership in Copenhagen Health Tech Hub and Barcelona Health Hub providing grant and partnership access, ADAPT-T2D Consortium involvement suggesting non-dilutive funding and clinical validation, Denmark-based with access to world-class digital health infrastructure and Sundhedsdatastyrelsen network, Niche focus on diabetes — one of the largest and fastest-growing chronic disease categories globally

Risk factors: No financial data publicly available — revenue, EBIT, and equity all unconfirmed, Likely pre-revenue or early-revenue startup with dependency on equity and grant funding, Single-product concentration (Line Portal) with no evidence of diversified revenue streams, Long hospital sales cycles (12–36 months) creating cash flow pressure, Highly competitive landscape including Dexcom Clarity, Medtronic CareLink, Glooko, and Tidepool, Ongoing MDR compliance costs (post-market surveillance, vigilance reporting) disproportionate for small team, Likely high customer concentration among a small number of Danish hospital departments, Geographic concentration risk with primary market limited to Denmark and broader EU

Revenue by geography

Revenue by product/service

Workforce by country

Signed-in users can see whether their own company is exposed to this vendor's disruption, plus the full sub-vendor list and country breakdowns, every in-scope compliance framework plus gaps and next steps, and alerts when any of it changes.

View the full interactive report